We Improve lives by making drug development easier for our customers
Our biopharmaceutical manufacturing facility (Darra, Australia) remains open during the COVID-19 pandemic. If you are working on a drug, a vaccine or a diagnostic to help battle Coronavirus, please contact us now for a fast consultation to see how we can work together for fast response to scale up and manufacturing.
Like the teams of scientists around the clock working researching new drugs or repurpose existing medications to halt the spread of the virus, Luina Bio scientists are ready to take the next step in scale-up and manufacturing. Luina Bio brings a wealth of contract manufacture capabilities and experience to the table, an invaluable component in advancing a potential COVID-19 vaccine candidate. It is one of Australia’s most experienced biopharmaceutical contract manufacturing organisations, helping bring biomanufacturing projects from early process development to market.
If you need process development and production support in the following areas:
- Recombinant proteins expression and purification,
- Plasmid DNA,
- Bacterial or yeast expression
- Lyophilisation
Luina Bio can find solutions to the most ambitious projects.
Luina Bio has been asked to participate in projects involving vaccines, diagnostic devices, co-medications and antiviral candidates from companies based in Australia and abroad. Our collaborations with Griffith University and several private companies are moving forward at speed.
Additional benefits to working with Australia are world-class researchers and state-of-the-art facilities, a streamlined regulatory framework, and generous tax incentives. Read more at Why our Clients Manufacture in Australia.
At Luina Bio, we are driven to do ambitious biopharmaceutical manufacturing every day that saves lives around the world. Let us, help you, help save the world from COVID-19. Our specialist scientists and project staff are available now for a consultation.
